Dr Heidi Taipale and colleagues from Finland investigated whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer’s disease.
A Finnish nationwide nested case–control study MEDALZ includes all community-dwelling individuals with newly diagnosed Alzheimer’s disease during 2005–2011, and up to 4 age-, sex-, and region of residence-matched comparison individuals for each case.
Data were extracted from Finnish nationwide health-care registers.
|Longer duration of use was not associated with risk of Alzheimer’s disease|
|American Journal of Gastroenterology|
PPI use was derived from purchases recorded in the Prescription register data since 1995 and modeled to drug use periods with PRE2DUP method.
Alzheimer’s disease was the outcome measure.
The research team found that PPI use was not associated with risk of Alzheimer’s disease with 3-year lag window applied between exposure and outcome.
Similarly, longer duration of use was not associated with risk of Alzheimer’s disease.
The team found that higher dose use was not associated with an increased risk.
Dr Taipale's team comments, "We found no clinically meaningful association between PPI use and risk of Alzheimer’s disease."
"The results for longer duration of cumulative use or use with higher doses did not indicate dose–response relationship."